Antithrombotic therapy in TAVI patients: changing concepts

Area of Science:

• Cardiology
• Vascular Medicine
• Pharmacology

Background:

• Transcatheter aortic valve implantation (TAVI) patients present unique clinical and demographic challenges for antithrombotic therapy.
• Ischemic and bleeding events remain significant concerns post-TAVI, necessitating optimized antithrombotic strategies.
• The evolving landscape of antiplatelet and anticoagulant medications offers new therapeutic possibilities.

Purpose of the Study:

• To review the current challenges and evolving evidence regarding antithrombotic therapy following TAVI.
• To critically assess the established dual antiplatelet therapy (DAPT) recommendation in light of recent findings.
• To explore the potential role of oral anticoagulation (OAC) and other antithrombotic regimens in TAVI patients.

Main Methods:

• Review of current clinical guidelines and recent scientific evidence on antithrombotic therapy post-TAVI.
• Analysis of the incidence and implications of ischemic and bleeding events in the TAVI population.
• Evaluation of the pharmacopeia of antiplatelet and anticoagulant drugs and their combinations.

Main Results:

• Dual antiplatelet therapy (DAPT) is the current standard, with oral anticoagulation (OAC) reserved for specific indications.
• Recent evidence questions the efficacy of DAPT, suggesting aspirin monotherapy or OAC may be superior in certain TAVI patient subgroups.
• Atrial fibrillation is common post-TAVI and contributes to thromboembolic risk, complicating antithrombotic choices.

Conclusions:

• Current antithrombotic recommendations for TAVI patients require reevaluation based on emerging evidence.
• Further large-scale randomized trials are essential to compare different antithrombotic strategies, including novel agents.
• Individualized antithrombotic therapy, balancing bleeding and thromboembolic risk, is crucial for this frail patient population.